The Effect of miR-210 Up-regulation on Proliferation and Survival of Mouse Bone Marrow Derived Mesenchymal Stem Cell

Neda Minayi¹, Shaban Alizadeh¹, Hosein Dargahi², Masoud Soleimani³, Zahra Kashani Khatib³, behnoosh tayebi⁴, Mozhe Mohammadian⁵, Sadegh Alijani¹, Farshid Karami¹

¹Hematology Department, Allied Medical School, Tehran University of Medical sciences, Tehran, Iran
²Health care services Department, Medical School, Tehran University of Medical sciences, Tehran, Iran
³Hematology Department, Tarbiat Modares University, Tehran, Iran
⁴Hematology Department, Qaem Hospital, Mashad University of Medical sciences, Mashhad, Iran
⁵Hematology Department, Tabriz University of Medical sciences, Tabriz, Iran

Corresponding Author: Shaban Alizadeh (Ph.D.)
Hematology Department, Allied Medical School, Tehran University of Medical sciences, Tehran, Iran
Email: Alizadehs@sina.tums.ac.ir

ABSTRACT
Background: Bone marrow derived mesenchymal stem cells (MSCs) are a population of multipotent progenitors which have the capacity of proliferation and differentiation into mesenchymal lineage cells. Hypoxia could promote the proliferation of MSCs. Micro-RNAs are endogenous RNAs that can play an important role in some processes such as proliferation and differentiation. MiR-210 could help for better proliferation of MSCs since this miRNA could activate HIF pathway. In current study we investigated if MSCs can preserve their differentiation and proliferation ability under normoxic conditions by upregulation of miR-210.

Materials and Methods: MSCs isolated from C57 BL/6 mice by flushing it’s femurs into the cell culture media. After 72 hours, MSCs which are plastic adherent cells were attached to the flask and non-adherent cells were removed. Subsequently, MSCs induced to differentiate into osteocytes and adipocytes with specific differentiation media in order to confirm their identity and multipotency. Then miR-210 was inserted in Lentivirus vectors and affected MSCs. In each passage, the number and viability of cells were evaluated.

Results: Comparison between miR-210 infected MSCs with control cells showed that miR-210 has ability to increase proliferation of MSCs significantly.

Conclusion: We showed that miR-210 has ability to induce proliferation of MSCs without any negative effect on their differentiation abilities. Further studies are needed for evaluation of probable effects of miR-210 mechanisms on MSCs proliferation.

Key words: Mesenchymal stem cells, MiR-210, HIF-1α

INTRODUCTION
MSCs are multipotent progenitors which reside in bone marrow, fat and some other tissues and can be isolated from various adult and fetal tissues.¹⁻³ In vivo and in vitro, they are able to proliferate and differentiate into osteoblasts, adipocytes, chondrocytes and a variety of cell lineages.⁴⁻⁶ Self-renewal potential⁷ and multipotency are the hallmarks of MSCs.⁸ MSCs comprise about 0.001% of bone marrow mononuclear cells.¹ For clinical purposes, we need a large-scale of MSCs, thus we must induce proliferation in them to generate adequate number of cells. Hypoxia could promote the proliferation of MSCs. This finding were reported in different sources derived MSCs. Hypoxia
enhances proliferation of human MSCs,9 rat MSCs,10 PB-MSCs11 and adipose-derived MSCs.12

MicroRNAs (miRNAs) are small conserved family of short (approximately 18–22 nucleotides) endogenous non-coding RNAs which are post-transcriptional negative regulators of protein-coding gene expression at the mRNA level via translational repression and/or mRNA degradation.13, 14 MiRNAs regulate gene expression via inhibition of RNA translation through binding to the 3’ untranslated regions (UTRs) of their target mRNAs by its seed sequence, 2–7 nucleotides in 5’ UTR, which is complementary to their target genes’ 3’ UTR.15-18 MicroRNAs genes are involved in regulation of a wide variety of cellular mechanisms including proliferation, differentiation, apoptosis, and metabolism13, 19-26 as well as angiogenesis and tumorigenesis.20, 27-31

Hypoxamirs are a group of hypoxia-induced miRNA molecules which are highly upregulated by hypoxia. MiR-210, one member of hypoxamirs family, is a direct transcriptional target of Hypoxia-inducible factor-1α (HIF-1α) which is robustly and ubiquitously expressed in a wide range of both normal and transformed hypoxic cells.15, 32-38

Hypoxia-inducible factor (HIF) is a heterodimeric transcription factor, which regulate the cellular response to hypoxia. HIF is composed of two α subunit (oxygen sensitive) and a β subunit (constitutively active). In normoxia, HIF-α is transcribed and translated but is rapidly degraded by the Von Hippel Lindau (VHL) protein.39-41 In hypoxia, HIF-1α is stabilized and accumulates for dimerization with HIF-β; this complex can bind to the specific sites in gene promoters named hypoxia response elements (HREs), and it transcriptionally regulates a variety of target genes.42-48 HIF1α directly binds to a highly conserved HRE on the proximal miR-210 promoter49 and upregulated miR-210 gene. A wide spectrum of miR-210 physiological roles includes cell proliferation, angiogenesis, mitochondrial metabolism, DNA repair and cell cycle regulation.34,35 Due to the role of miR-210 in stem cell survival and proliferation,44 in current study, we investigated induction of mir-210 upregulation on proliferation of mouse mesenchymal stem cells in normoxic conditions.

MATERIALS AND METHODS
Isolation, Culture, and Proliferation of MSC
Mesenchymal stem cells were collected from male C57Bl/6 mice by flushing the femurs with Dulbecco’s modified Eagle’s medium-low glucose (DMEM, Gibco) supplemented with 10% fetal bovine serum (Invitrogen), 100 U/ml penicillin, and 100 μg/mL streptomycin (Invitrogen). The obtained suspension was centrifuged at 300× g for 5 min. The pellet was resuspended in growth medium and incubated in 5% CO2 at 37 °C for 72h. After 3 days, the medium containing the non-adherent hematopoietic cells was removed from the flask, and fresh medium was replaced. After approximately 4 days, 7 days from isolation, the primary cells were passaged when BMSCs reached 80% confluency. Adherent cells were retrieved by trypsinization and then replated.

Differentiation Assays
MSCs were plated in duplicate in 24-well tissue culture plate, 6×10⁴ cells per well, and then induced to differentiate. The cells were chosen from third passage. For adipogenic differentiation of MSCs, cells were cultured in adipocytic differentiation medium (100nM dexamethasone, 50μm indomethacine, 0.5mM isobutyl-1-methyl xanthine) for 14 days and stained with Oil Red O (Sigma). For osteogenic differentiation of MSCs, cells were cultured in osteogenic differentiation medium (50μM ascorbic acid, 10mM beta-glycerol-3-phosphate, and 100nM dexamethasone) for 21 days and stained with Alizarin Red S (Sigma).

Cloning pre- miR-210
pLenti-III-mir-GFP containing the precursor of miR-210 were prepared from stem cell technology institute. (Figure-1: Map of plasmid)
**Lentivirus Production & Infection of Target Cells**

Lentiviral vectors expressing the transgene were produced by transfecting three plasmid systems (Packaging plasmid ps-PAX2, envelope plasmid pMD2.G and pLenti-III-mir-GFP vector plasmids with insert fragments) into the producer cells (HEK-293) using the calcium–phosphate method. Culture medium was replaced 16 hours post-transfection. Vector-containing supernatants were collected 24h, 48h and 72h post-transfection, then centrifuged, filtered and pooled. One day before transduction, MSCs (from passage 4) were plated in the 24-well plates (35× 10^3 cells/well) and then transduced with 500µl of lentiviral vectors containing pLenti-miR-210 and pLenti (without miR-210) as control; one well remained as negative control. The supernatant containing vectors that collected from HEK239 was added directly to MSCs without using any reagent for transduction. After 24h, the medium was replaced with fresh complete medium; and after 48h, the efficiency of transduction was evaluated by an invert fluorescent microscope. The infected cells were selected by means of puromycin with optimal effective dose of 2µg/ml. 2µg/ml of puromycin was add into the passage 1-3 in order to kill non-transfected cells.

**Evaluating the Effect of miR-210 on MSCs Proliferation**

Every 72h, cells were trypsinized from each well (plasmid with and without miRNAs, and negative control) and counted with hemocytometer; their viability was quantified with trypan-blue assay.

**Statistical analysis**

Data were analyzed by Student’s t test using SPSS version 16.00. P value less than 0.01 was considered as statistically significant.

**RESULTS**

**MSCs Isolation, Culture and Differentiation**

MSCs were isolated from the femurs of the C57Bl/6 mice by flushing. Non-adherent cells were removed after 3 days and fresh medium was added to the adherent cells. Approximately 4 days after isolation, spindle-shaped morphology was seen (Figure 2).

![Fig 2. Mesenchymal stem cells 96h after isolation (a), Mesenchymal stem cells 14 days after isolation-3th passage (b)](image)

Differentiation assays, were carried out in order to confirm the osteogenic and adipogenic potential of cells. Alizarin Red staining for osteocytes and Oil Red staining for adipocytes were performed. Intracellular lipid vesicles in mature adipocytes were stained bright red with Oil Red stain; and extracellular calcium deposits in osteocytes were stained bright orange-red with Alizarin Red stain. (Figure 3)

The isolated cells were identified as MSCs by their adherence to plastic flasks, spindle-shaped morphology and differentiation potential.
Recombinant lentivirus production and transduction of MSCs

In order to produce the lentiviral particles expressing pre-miR-210, packaging plasmid pSPAX2, envelope plasmid pMD2.G and pLenti-III-mir-GFP vector with inserted fragments were co-transfected into the HEK-293 using the calcium-phosphate method. 24, 48, and 72h after transfection, Lentiviral particles were collected from HEK293 supernatant. MSCs from 4th passage were cultured in 24-well plates, $35 \times 10^3$ cells/well and infected by 500μl of supernatants. 48h later, the GFP positive cells were seen by fluorescent microscope, about 50% of MSCs were GFP positive. Because the infected cells were puromycin resistance, cells were cultured in medium containing 2μg/ml of puromycin in order to select infected cells. At the end of passage 3, 90% of cells were GFP positive. (Figure 4)

The number of passages, proliferation and viability of MSCs

Cell counting performed every 72h using hemocytometer; and cell viability of were assessed using trypan-blue assay. Cells proliferation evaluation has been continued up to 40 days. Results are shown in Table1 and Fig 5.
Table 1. Cell Number (the average of duplicate pellets) and Viability of Mesenchymal Stem Cells in Control Group, Cells Containing Plasmid without miR-210 Group and Cells Containing Plasmid with miR-210 Group, in Each Passage.

| Passage number | Control cells | Plasmid without miR-210 | Plasmid with miR-210 | Viability of cells containing Plasmid with miR-210 |
|----------------|---------------|--------------------------|----------------------|-----------------------------------------------|
| P              | 35000         | 35000                    | 35000                | 90%                                           |
| P0             | 304000        | 267000                   | 272000               | 70%                                           |
| P1             | 309000        | 251000                   | 262000               | 75%                                           |
| P2             | 310000        | 259000                   | 283000               | 85%                                           |
| P3             | 303000        | 288000                   | 317000               | 85%                                           |
| P4             | 290000        | 280000                   | 351000               | 90%                                           |
| P5             | 283000        | 276000                   | 366000               | 85%                                           |
| P6             | 279000        | 265000                   | 374000               | 85%                                           |
| P7             | 263000        | 258000                   | 375000               | 85%                                           |
| P8             | 260000        | 252000                   | 369000               | 85%                                           |
| P9             | 256000        | 246000                   | 362000               | 85%                                           |
| P10            | 253000        | 239000                   | 359000               | 80%                                           |
| P11            | 252000        | 237000                   | 355000               | 80%                                           |

DISCUSSION

Most previous studies investigated mesenchymal stem cell proliferation in hypoxic conditions. Hypoxia can regulates cell proliferation by the means of hypoxia-inducible factors (HIFs). Induction of miR-210, major hypoxia-inducible miRNAs, is a feature of the hypoxic response in both normal and transformed cells. MiR-210 functioned by targeting MNT, a known antagonist of MYC-dependent transcriptional activation and cell growth. Inhibition of MNT leads to activation of C-MYC indirectly. C-MYC is a basic-helix-loop-helix/leucine zipper (bHLH/LZ) transcription factor that controls the cell-cycle progression. The ability
of MYC to promote cell proliferation depends on its dimerization with MAX.⁴⁹,⁵³-⁵⁶ MYC-MAX heterodimers bind to Miz1 at the transcription initiator element (INR) of the CDKN1A gene and consequently inhibit CDKN1A (coding p21) which results in cell cycle progression. Additionally, MYC-MAX heterodimers can bind to E-box element (CACGTG) in the intron directly, and to the GC-rich region of the promoter through transcription factor Sp1 which leads to CDC25A expression and subsequently cell cycle progress. In contrast with former researches, in the current study, we investigated miR-210 over expression effects on mesenchymal stem cells proliferation in normoxic condition.⁵⁶-⁵⁸ MiR-210 may mediate the proliferation and survival of MSCs by targeting MNT, a known MYC antagonist.⁵³

Several studies indicated that MSCs are highly sensitive to oxygen pressure and hypoxia facilitates their proliferation. Ren et al (2006) described that under low oxygen tension (8% O₂), Balb/c mice derived MSCs exhibited high proliferation potential.⁵⁹ In Grayson et al (2007) study on human mesenchymal stem cells (hMSCs) under hypoxic atmospheres (2% O₂), an approximate 9-fold expansion was observed at each passage for hypoxic cells, whereas under normoxic atmospheres (20% O₂) only 5-fold expansion was seen in each passage.⁹ In 2007 Fehrer et al., determine the proliferation capacity of MSCs at 3% and 20% pO₂ in long-term culture (100 days) and represented that under ambient oxygen tension cell growth declined after several passages, whereas cells cultured in hypoxic conditions maintain the ability to proliferate.⁶⁰ Another study done by Lee et al., (2008) indicated that Adipose-derived stem cells (ADSCs) which exposed to low O₂ concentration demonstrated better survival and proliferation in comparison with ADSCs under ambient O₂ concentration.¹² Dos Santos et al., (2009) indicated that human bone marrow (BM) MSC exhibited an early start of the exponential growth phase and subsequently a higher fold increase under hypoxia than normoxia.⁶¹ Wei-li et al., (2011) illustrated that hypoxia could enhance proliferation of PB-MSCs.¹¹ Wang et al in 2012 demonstrated that hypoxia (3% O₂ treatment) can increase rat MSC proliferation by upregulation of phosphorylated p38 MAPK.¹⁰

In the present study, we showed that miR-210 over expression leads to induction of mesenchymal stem cells proliferation in normoxic condition. Our results were in agreement with most studies in this area unless they investigated cell proliferation in hypoxic conditions and we just induced miR-210 in mesenchymal stem cells and studied its effects on MSCs expansion.

ACKNOWLEDGEMENT

This study was done in faculty of allied medical sciences of Tehran University of medical sciences and supported by grants from the Tehran University of medical sciences (research project number 91-02-3116939). The authors appreciatively thank the research committee of the faculty, all authorities and office worker of the research assistance of Tehran University. The authors would like to thank Dr. Soleimani for the kind gift of pLenti-III-mir-GFP plasmid.

REFERENCES

1. Arai F, Ohneda O, Miyamoto T, Zhang XQ, Suda T. Mesenchymal stem cells in perichondrium express activated leukocyte cell adhesion molecule and participate in bone marrow formation. J Exp Med. 2002;195(12):1549-63.
2. Im Gi, Shin YW, Lee KB. Do adipose tissue-derived mesenchymal stem cells have the same osteogenic and chondrogenic potential as bone marrow-derived cells? Osteoarthritis Cartilage. 2005;13:845-53.
3. Campagnoli C, Roberts IA, Kumar S. Identification of mesenchymal stem/progenitor cells in human first-trimester fetal blood, liver, and bone marrow. Blood. 2001;98:2396-402.
4. Caplan AI. Mesenchymal stem cells. J Orthop Res. 1991;9(5):641-50.
5. M O, AJ F. Stromal stem cells: marrow-derived osteogenic precursors. Ciba Found Symp. 1988;136:42-60.
6. MK M, MA T, JD M. Phenotypic and functional comparison of cultures of marrow-derived mesenchymal stem cells (MSCs) and stromal cells. J Cell Physiol Rev. 1998;176:57-66.
7. Morisco C, de Fraipont F, Richard MJ, Marchand M, Savatier P, Bosco D, et al. Human bone marrow mesenchymal stem cells can express insulin and key transcription factors of the endocrine pancreas developmental pathway upon genetic and/or
microenvironmental manipulation in vitro. Stem Cells. 2005;23(4):594-603.

8. Friedenstein AJ, Gorskaja JF, Kulagina NN. Fibroblast precursors in normal and irradiated mouse hematopoietic organs. Exp Hematol. 1976;4(5):267-74.

9. Ma T, Grayson WL, Zhao F, Bunnell B. Hypoxia enhances proliferation and tissue formation of human mesenchymal stem cells. Biochem Biophys Res Commun. 2007;358:948-53.

10. Wang Y, Yang J, Li H, Wang X, Zhu L, Fan M, et al. Hypoxia Promotes Dopaminergic Differentiation of Mesenchymal Stem Cells and Shows Benefits for Transplantation in a Rat Model of Parkinson’s Disease. PLoS One. 2013;8(1):1-12.

11. Fu WL, Jia ZQ, Wang WP, Zhang JY, Fu X, Duan XN, et al. Proliferation and apoptosis property of mesenchymal stem cells derived from peripheral blood under the culture conditions of hypoxia and serum deprivation. Chin Med J 2011;124(23):3959-67.

12. Lee EY, Xia Y, Kim WS, Kim MH, Kim TH, Kim KJ, et al. Hypoxia-enhanced wound-healing function of adipose-derived stem cells: Increase in stem cell proliferation and up-regulation of VEGF and bFGF. Wound Repair and Regeneration. 2009;17(4):540-7.

13. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. cell. 2004;116(2):281-97.

14. Rana TM. Illuminating the silence: understanding the structure and function of small RNAs. Nature reviews Molecular cell biology. 2007;8(1):23-36.

15. Huang X, Ding L, Bennewith KL, Tong RT, Welford SM, Ang KK, et al. Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation. Molecular cell. 2009;35(6):856-67.

16. Bartel DP. MicroRNAs: target recognition and regulatory functions. cell. 2009;136(2):215-33.

17. AkbarPourfathollah A, Abroun S. Mir-155 Downregulation by miRCURY LNA™ microRNA Inhibitor Can Increase alpha Chain Hemoglobin Expression in Erythroleukemic K562 Cell Line. International Journal of Hematology-Oncology and Stem Cell Research. 2010;4(2).

18. Kouhkan F, Alizadeh S, Kaviani S, Soleimani M, Pourfathollah AA, Amirizadeh N, et al. mir-155 down regulation by LNA inhibitor can reduce cell growth and proliferation in PC12 cell line. Avicenna Journal of Medical Biotechnology. 2011;3(2):61.

19. Calin GA, Liu C-G, Sevignani C, Ferracin M, Felli N, Dumitru CD, et al. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proceedings of the National Academy of Sciences of the United States of America. 2004;101(32):11755-60.

20. Farh KK-H, Grimson A, Jan C, Lewis BP, Johnston WK, Lim LP, et al. The widespread impact of mammalian MicroRNAs on mRNA repression and evolution. Science. 2005;310(5755):1817-21.

21. Filipowicz W, Jaskiewicz L, Kolb FA, Pillai RS. Post-transcriptional gene silencing by siRNAs and miRNAs. Current opinion in structural biology. 2005;15(3):331-41.

22. Karp X, Ambros V. Encountering microRNAs in cell fate signaling. Science. 2005;310(5752):1288-9.

23. Miska EA. How microRNAs control cell division, differentiation and death. Current opinion in genetics & development. 2005;15(5):563-8.

24. Seila AC, Sharp PA. Small RNAs tell big stories in Whistler. Nature cell biology. 2008;10(6):630-3.

25. Guarnieri DJ, DiLeone RJ. MicroRNAs: a new class of gene regulators. Annals of medicine. 2008;40(3):197-208.

26. Leung AK, Sharp PA. microRNAs: a safeguard against turmoil? cell. 2007;130(4):581-5.

27. Croce CM, Calin GA. miRNAs, cancer, and stem cell division. cell. 2005;122(1):6-7.

28. He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S, et al. A microRNA polycistron as a potential human oncogene. Nature. 2005;435(7043):828-33.

29. Iorio MV, Ferracin M, Liu C-G, Veronese A, Spizzo R, Sabbioni S, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer research. 2005;65(16):7065-70.

30. Liu C-G, Calin GA, Meloon B, Gamliel N, Sevignani C, Ferracin M, et al. An oligonucleotide microchip for genome-wide microRNA profiling in human and mouse tissues. Proceedings of the National Academy of Sciences of the United States of America. 2004;101(26):9740-4.

31. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435(7043):834-8.

32. Matthew R, Simon MC. mir-210: a sensor for hypoxic stress during tumorigenesis. Molecular cell. 2009;35(6):737-8.

33. Ivan M, Harris AL, Martelli F, Kulshreshtha R. Hypoxia response and microRNAs: no longer two separate worlds. Journal of cellular and molecular medicine. 2008;12(5a):1426-31.

34. Giannakakis A, Sandultzopoulos R, Greshock J, Liang S, Huang J, Hasegawa K, et al. mir-210 links hypoxia with cell cycle regulation and is deleted in human epithelial ovarian cancer. Cancer biology & therapy. 2008;7(2):255-64.
35. Fasanaro P, D’Alessandra Y, Di Stefano V, Melchionna R, Romani S, Pomplilio G, et al. MicroRNA-210 modulates endothelial cell response to hypoxia and inhibits the receptor tyrosine kinase ligand Ephrin-A3. Journal of Biological Chemistry. 2008;283(23):15878-83.

36. Pulkkinen K, Malm T, Turunen M, Koistinaho J, Ylä-Herttuala S. Hypoxia induces microRNA miR-210 in vitro and in vivo: Ephrin-A3 and neuronal pentraxin 1 are potentially regulated by miR-210. FEBS letters. 2008;582(16):2397-401.

37. Kulshreshtha R, Ferracin M, Wojcik SE, Garzon R, Alder H, Agosto-Perez FJ, et al. A microRNA signature of hypoxia. MOLECULAR AND CELLULAR BIOLOGY. 2007;27(5):1859-67.

38. Crosby ME, Kulshreshtha R, Ivan M, Glazer PM. MicroRNA regulation of DNA repair gene expression in hypoxic stress. Cancer research. 2009;69(3):1221-9.

39. Adams J, Difazio L, Rolandelli R, Lujan J, Hasko G, Csoka B, et al. HIF-1: a key mediator in hypoxia (Review). Acta Physiologica Hungarica. 2009;96(1):19-28.

40. Corn PG. Role of the ubiquitin proteasome system in renal cell carcinoma. BMC biochemistry. 2007;8(Suppl 1):S4.

41. Weidemann A, Johnson R. Biology of HIF-1α. Cell Death & Differentiation. 2008;15(4):621-7.

42. Peterson KM, Aly A, Lerman A, Lerman LO, Rodriguez-Porcel M. Improved survival of mesenchymal stromal cell after hypoxia preconditioning: role of oxidative stress. Life sciences. 2011;88(1):65-73.

43. Chin BY, Jiang G, Wegiel B, Wang HJ, MacDonald T, Zhang XC, et al. Hypoxia-inducible factor 1α stabilization by carbon monoxide results in cytoprotective preconditioning. Proceedings of the National Academy of Sciences. 2007;104(12):5109-14.

44. Kim HW, Haider HK, Jiang S, Ashraf M. Ischemic preconditioning augments survival of stem cells via miR-210 expression by targeting caspase-8-associated protein 2. Journal of Biological Chemistry. 2009;284(48):33161-8.

45. Pasha Z, Wang Y, Sheikh R, Zhang D, Zhao T, Ashraf M. Preconditioning enhances cell survival and differentiation of stem cells during transplantation in infarcted myocardium. Cardiovascular research. 2008;77(1):134-42.

46. Wang J-a, Chen T-I, Jiang J, Shi H, Gui C, Luo R-h, et al. Hypoxic preconditioning attenuates hypoxia/reoxygenation-induced apoptosis in mesenchymal stem cells. Acta Pharmacologica Sinica. 2008;29(1):74-82.

47. Jiang B-H, Semenza GL, Bauer C, Marti HH. Hypoxia-inducible factor 1 levels vary exponentially over a physiologically relevant range of O2 tension. American Journal of Physiology-Cell Physiology. 1996;271(4):C1172-C80.

48. Semenza GL, Jiang B-H, Leung SW, Passantino R, Concordet J-P, Maire P, et al. Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. Journal of Biological Chemistry. 1996;271(51):32529-37.

49. Huang X, Le Q-T, Giaccia AJ. MiR-210–micromanager of the hypoxia pathway. Trends in molecular medicine. 2010;16(5):230-7.

50. Nie Y, Han B-M, Liu X-B, Yang J-J, Wang F, Cong X-F, et al. Identification of MicroRNAs involved in hypoxia-and serum deprivation-induced apoptosis in mesenchymal stem cells. International journal of biological sciences. 2011;7(6):762.

51. W C, Ch L, J P, M P, L M, C Y, et al. Survival of hypoxic human mesenchymal stem cells is enhanced by a positive feedback loop involving miR-210 and hypoxia-inducible factor 1. J Vet Sci. 2013;14(1):69-76.

52. Chan SY, Loscalzo J. MicroRNA-210: a unique and pleiotropic hypoxamir. Cell Cycle. 2010;9(6):1072-83.

53. Zhang Z, Sun H, Dai H, Walsh R, Imakura M, Schelter J, et al. MicroRNA miR-210 modulates cellular response to hypoxia through the MYC antagonist MNT. Cell Cycle. 2009;8(17):2756-68.

54. Hurlin P, Queva C, Eisenman R. Mnt: a novel Max-interacting protein and Myc antagonist. C-Myc in B-Cell Neoplasia: Springer; 1997. p. 115-21.

55. Hurlin PJ, Queva C, Eisenman RN. Mnt, a novel Max-interacting protein is coexpressed with Myc in proliferating cells and mediates repression at Myc binding sites. Genes & development. 1997;11(1):44-58.

56. L H. Carrot and stick: HIF-a engages c-Myc in hypoxic adaptation. Cell Death and Differentiation. 2008;15:672-7.

57. J G, J B, Ch H, J D, M S. HIF-2α Promotes Hypoxic Cell Proliferation by Enhancing c-Myc Transcriptional Activity. Cancer Cell 2007;11:335-47.

58. J G, C T, M S. HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferation. Cancer Cell August 2007;12(2):108-13.

59. H R, Y C, Q Z, J L, C Z, L L, et al. Proliferation and differentiation of bone marrow stromal cells under hypoxic conditions. Biochemical and Biophysical Research Communications. 2006;347:12-21.
60. Fehrer C, Brunauer R, Laschober G, Unterluggauer H, Reitinger S, Kloss F, et al. Reduced oxygen tension attenuates differentiation capacity of human mesenchymal stem cells and prolongs their lifespan. Aging cell. 2007;6(6):745-57.

61. F DS, P A, J B, M A, C DS, J C. Ex Vivo Expansion of Human Mesenchymal Stem Cells: A More Effective Cell Proliferation Kinetics and Metabolism Under Hypoxia. J Cell Physiol. 2010; 223: 27-35.